{"anticipatedPostingDate":"2027-01","denomUnitsSelected":"Participants","description":"PFS was defined as the time from start of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever came first. Kaplan-Meier method was used for analysis. PFS data was censored on the date of the last radiological assessment of measured lesions documenting absence of PD for participants without objective tumor progression and were still on study at the time of an analysis, were given antitumor treatment other than the study treatment or stem cell transplant (included donor lymphocyte infusion) or were removed from study prior to documentation of objective tumor progression. Participants who lacked an evaluation of tumor response after their first dose had their event time censored at 1 day.","reportingStatus":"NOT_POSTED","timeFrame":"From the first dose of study treatment to first documentation of objective tumor progression or death due to any cause or censoring, whichever came first (approximately 61.7 months)","title":"Progression Free Survival (PFS) Per BICR (Cheson 2007) by Central CD30 Assessment","type":"SECONDARY"}